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Abstract 
Background: Acute myeloid leukemia (AML) is an incurable disease with fatal infections or relapse being the main 
causes of death in most cases. In particular, the severe infections occurring in these patients before or during any 
treatment suggest an intrinsic alteration of the immune system. In this respect, IL-17-producing T helper (Th17) 
besides playing a key role in regulating inflammatory response, tumor growth and autoimmune diseases, have been 
shown to protect against bacterial and fungal pathogens. However, the role of Th17 cells in AML has not yet been 
clarified.
Methods: T cell frequencies were assessed by flow cytometry in the peripheral blood of 30 newly diagnosed AML 
patients and 30 age-matched healthy volunteers. Cytokine production was determined before and after culture of T 
cells with either Candida Albicans or AML blasts. Statistical analyses were carried out using the paired and unpaired 
two-tailed Student’s t tests and confirmed with the non parametric Wilcoxon signed-rank test.
Results: A strong increase of Th17 cells producing immunosuppressive IL-10 was observed in AML patients com-
pared with healthy donors. In addition, stimulation of AML-derived T cells with a Candida albicans antigen induced 
significantly lower IFN-γ production than that observed in healthy donors; intriguingly, depletion of patient Th17 cells 
restored IFN-γ production after stimulation. To address the role of AML blasts in inducing Th17 alterations, CD4+ cells 
from healthy donors were co-cultured with CD33+ blasts: data obtained showed that AML blasts induce in healthy 
donors levels of IL-10-producing Th17 cells similar to those observed in patients.
Conclusions: In AML patients altered Th17 cells actively cause an immunosuppressive state that may promote infec-
tions and probably tumor escape. Th17 cells could thus represent a new target to improve AML immunotherapy.
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Background
Acute myeloid leukemia (AML) is the most common 
form of acute leukemia in adults [1] and current treat-
ments remain unsatisfactory. Serious infections, resist-
ance to therapy and relapses are the main causes of 
mortality among patients [2–4]. In particular, the high 
frequency and severity of infections (especially fungal) 
before or during chemotherapy are probably due to a 
severe adaptive immunity dysfunction directly induced 
by the disease [5, 6]. This immunosuppressive state may 
also be responsible for the continuous recurrence of 
AML and for the failure of immunotherapies [7], with the 
exception of allogeneic transplantation [8].
Although several studies identified different immu-
nosuppressive mechanisms operating in AML [9–13], 
the precise link between immune alterations, leukemia 
immune escape and infections has not yet been eluci-
dated. Investigating in this direction, T helper cells seem 
to be important players with Th17 cells being one of the 
most intriguing and not fully understood subset so far 
[14].
Th17 cells show a pleiotropic role in the inflammatory 
response, autoimmune disorders and tumors [15–19]. 
In the latter context, they showed remarkable epigenetic 
plasticity [14] and the ability to transdifferentiate into T 
helper 1-like cells (secreting IFN-γ and showing tumor 
suppressor activity) [19–21] or T regulatory (Treg)-like 
cells (secreting IL-10, with immunosuppressive functions 
and probably tumor promoter activity) [22–25].
Moreover, Th17 cells have the important task of coor-
dinating the immune defense against bacterial and fun-
gal infections and physiologically protect humans against 
these diseases [26–28]. However, the behavior of Th17 
in several tumor types and hematologic malignancies 
remains to be clarified [22, 29–31]. In particular, different 
studies on AML have attributed a controversial pathoge-
netic role and divergent prognostic values to these cells 
[31–36] but have not succeeded in establishing a link 
between the reported alterations and the infections to 
which these patients are subject.
We showed that Th17 cells with a double production of 
IL-17 and IL-10 were strongly increased in AML patients 
and that ex  vivo patient immune response to an infec-
tious antigen, such as Candida Albicans (C. Albicans), 
was significantly reduced by Th17. Finally, we found that 
blasts, co-cultured with CD4+ cells from healthy donors, 
were able to change the frequency and cytokine profile of 
T cells, and in particular of Th17, in a similar manner to 
that observed in patients.
All of the above data support the hypothesis that the 
increase in IL-10+ Th17 cells in AML is a mechanism 
developed by the disease to create an immunosuppres-
sion state which, given the stem-like features and long 
life of Th17 cells [14, 37], may be durable and ultimately 
favor infections, protecting leukemia cells from immune 
control.
Methods
Blood samples and PBMCs collection
After obtaining the patient’s informed consent and the 
approval of the local ethics committee, in accordance 
with the Declaration of Helsinki, samples of peripheral 
blood (15–20  ml) were collected from 30 newly diag-
nosed AML patients before any treatment was started 
and from 30 age-matched (±10 years) healthy volunteers 
(HV). AML patients were diagnosed according to the 
French American-British (FAB) classification system [38]. 
Patient and HV characteristics are reported in Table  1. 
Blood samples were collected in sterile EDTA tubes and 
Table 1 Patient and HV characteristics
FAB French-American-British, chr chromosome, t translocation, Inv inversion, Del 
deletion, wt wild type, mut mutated.
HV AML
No. patients 30 30
Gender
 Male 15 (50%) 14 (47%)
 Female 15 (50%) 16 (53%)
Median age, years (range) 63 (38–87) 68 (35–85)
Subtype according to FAB classification
 M0–M1 6 (20%)
 M2 9 (30%)
 M4 4 (13.3%)
 M5 9 (30%)
 M6 1 (3.3%)
 M7 1 (3.3%)
Karyotype
 Normal 14 (47%)
 Undefined 4 (13%)
 Complex 3 (10%)
Trisomy chr 8 3 (10%)
 t(8–21) 2 (7%)
 Tetrasomy chr 21 1 (3%)
 Inv chr 3 1 (3%)
 Del chr 7 1 (3%)
 Del chr 20 1 (3%)
Molecular mutations
 FLT3/NPM wt 17 (57%)
 FLT3 ITD 4 (13%)
 FLT3 mut NPM mut 3 (10%)
 FLT3 mut NPM wt 1 (3%)
 FLT3 wt NPM mut 1 (3%)
 AML-ETO 2 (7%)
 Undefined 2 (7%)
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mononuclear cells (PBMCs) were separated by density 
gradient centrifugation using Lymphosep (Biowest) and 
frozen in 90% heat inactivated fetal bovine serum (FBS) 
(PAA) and 10% dimethylsulfoxide (Sigma Aldrich).
CD4+ cell isolation and culture
In order to avoid contamination by CD4+ cells that 
release IL-17, such as macrophages [37], PBMCs were 
thawed and human CD4+ T cells were isolated by neg-
ative depletion of CD8+, CD14+, CD15+, CD16+, 
CD19+, CD36+, CD56+, CD123+, TCR y/δ and 
CD235a+, using the CD4+ T cell isolation kit (Milte-
nyi Biotec). In this way also AML blasts, where present, 
were included in the subsequent analysis. Cells were cul-
tured in RPMI 1640 medium (PAA) supplemented with 
10% heat inactivated FBS, 2  mM  l-glutamine (Euro-
clone), penicillin (100 U/ml) and streptomycin (100 μg/
ml) (PAA). CD4+ cells were primed for 24  h at 37°C 
with IL-6 (30 ng/ml) (Miltenyi Biotec) or TGF-β (10 ng/
ml) (Abcam) or a combination of IL-6 and TGF-β. T 
cells were then incubated for 5  h at 37°C with phorbol 
12-myristate-13-acetate (PMA, 50 ng/ml) and ionomycin 
(1 μg/ml) (Invitrogen) in the presence of GolgiStop Pro-
tein Transport Inhibitor (BD Pharmingen). An unstimu-
lated control prepared by incubating CD4+ cells with 
GolgiStop Protein Transport Inhibitor only was included 
for each experiment.
Immunophenotypic analysis of T cells
After stimulation, cells were fixed and permeabilized 
with Cytofix/Cytoperm (BD Biosciences) then immu-
nophenotyped for intracellular IFN-γ, IL-4 and IL-17A 
expression using the human TH1/TH2/TH17 phenotyp-
ing kit (BD Pharmingen) following the manufacturer’s 
protocol. For Treg analysis, naïve PBMCs were stained 
with anti-human FITC CD4 (0.6  μg/ml, clone SK3; BD 
Biosciences) and anti-human APC-Cy7 CD25 (2.5  μg/
ml, clone M-A251; BD Biosciences) for 10 min at 4°C in 
the dark. After incubation, cells were fixed and permea-
bilized and then stained with anti-human APC FoxP3 
(1:11, clone 3G3; Miltenyi Biotec) for 30  min at 4°C in 
the dark. Appropriate isotype controls were included for 
each sample.
Cytokine secretion analysis
Stimulated CD4+ cells were washed with cold PBS con-
taining 0.5% (v/v) bovine serum albumin (BSA) (Sigma 
Aldrich) and 2 mM of EDTA and analyzed using human 
IL-17 and IL-10 secretion assay—detection kits (Milte-
nyi Biotec). Briefly, cells were stained with IL-17 and 
IL-10 catch reagents for 5  min on ice, incubated for 
45 min at 37°C to allow cytokine secretion and then with 
anti-human PE IL-17A, anti-human APC IL-10 and anti-
human FITC CD4 for 10  min on ice, according to the 
manufacturer’s instructions. Samples were washed and 
suspended for flow cytometric analysis.
CD33+ cells isolation
Circulating CD33+ cells were magnetically isolated from 
AML PBMCs in two steps: first, CD4+ and blast cells 
were negatively purified using the T cell isolation kit, as 
already described; subsequently, CD33+ cells were puri-
fied with CD33 MicroBeads kit (Miltenyi Biotec) follow-
ing the manufacturer’s instructions.
Direct and indirect allogeneic co‑cultures
For direct co-cultures, CD33+ cells isolated from 15 
AML patients and allogeneic CD4+ T cells obtained 
from 15 HV as previously reported were co-seeded in 
1:1, 1:5 and 1:10 ratios. For indirect co-cultures, purified 
CD4+ cells were seeded in the bottom part of the 6-well 
plates of transwell cell culture system (pore size 0.4 μm; 
Costar Corp.), whereas CD33+ cells were seeded in the 
corresponding transwell cell culture inserts. In addi-
tion, each cell type was seeded individually in 6-well 
plates for single culture as control. All samples were cul-
tured in complete medium and stimulated as previously 
described. At the end of stimulation, T cell immunophe-
notypic and cytokine secretion analysis was performed.
T cell activation with C. Albicans and isolation 
of IL‑17‑secreting cells
CD4+ cells (2.5 × 106) were stimulated for 24 h at 37°C 
with 1 μg/ml of C. Albicans peptides (JPT, Berlin, Ger-
many). During the last 5  h of incubation, cells were 
maintained in the presence of GolgiStop Protein Trans-
port Inhibitor (BD Pharmingen). Samples were centri-
fuged at 4°C, incubated with 2 mM of EDTA in PBS for 
10 min at 37°C, washed with 0.5% BSA and 0.1% sodium 
azide in PBS. Cells were then depleted of IL-17-secreting 
cells using the IL-17 Secretion Assay—Cell Enrichment 
and Detection Kit (Miltenyi Biotec). The IL-17 specific 
catch reagent was attached to the cell surface as previ-
ously described, after which cells were labeled with anti-
human PE IL-17A and stained with anti-PE microbeads. 
IL-17-secreting cells were separated through two con-
secutive column runs, according to the manufacturer’s 
instructions. Negative fraction was cultured for a further 
24 h in complete medium supplemented with 1 μg/ml of 
C. Albicans peptides and then analyzed for intracellular 
IFN-γ expression using the human TH1/TH2/TH17 phe-
notyping kit (BD Pharmingen). A sample stimulated with 
C. Albicans for 48 h without depletion of IL-17-secreting 
cells was added as control.
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Flow cytometry
Flow cytometric analysis were performed using a FAC-
SCanto flow cytometer (Becton–Dickinson) equipped 
with 488  nm (blue) and 633 (red) lasers and 50,000 
events were recorded for each sample. The acquisition 
and analysis gates were set on lymphocytes based on 
forward (FSC) and side scatter (SSC) properties of cells. 
FSC and SSC were set in a linear scale. For more exten-
sive analysis, gates were set on CD4+ T cell subsets. 
Flow cytometry data were analyzed with Diva Software 
(Becton–Dickinson).
Statistical analysis
Data were summarized by descriptive statistics 
(mean ± standard deviation for continued variables and 
frequency and percentage for categorical variables). Sta-
tistical analyses were carried out using the paired and 
unpaired two-tailed Student’s t tests and confirmed with 
the non parametric Wilcoxon signed-rank test. P values 
<0.05 were considered as significant.
Results
Alterations in the T cells frequency in peripheral blood 
of AML patients
We first focused on the frequency of CD4+ T cells (Th1, 
Th2, Th17 and Tregs) in the peripheral blood of 30 newly 
diagnosed untreated AML patients characterized by kar-
yotype and molecular biology mutations (Table  1) and 
30 sex- and age-matched HV. Given the controversies 
over the different Th17 polarization methods [39–43], 
we stimulated CD4+ cells isolated through a negative 
immunomagnetic system in serum-containing media 
with IL-6 and TGF-β alone and in combination. As no 
significant differences were observed (data not shown), 
Th1, Th2 and Th17 analyses were performed with IL-6 
alone, thereby reducing the risk of the TGF-β-mediated 
induction or inhibition of other cytokines.
As shown in Figure  1a, b, flow cytometric analysis 
revealed that the frequencies of T helper populations 
were altered in AML patients in comparison to healthy 
donors. In particular, Th1 and Th2 percentages were 
lower in patients (4.0 ± 2.1 and 0.8 ± 0.6% respectively) 
than in controls (12.8 ± 4.3 and 2.9 ± 1.8% respectively), 
whereas Th17 cells showed a 1.5-fold increase in AML 
patients compared to HV (P = 0.013) (Figure 1c). All the 
observed differences were statistically significant.
In addition the frequency of circulating Tregs was 
performed in unstimulated PBMCs by flow cytom-
etry. CD4+ cells with mean fluorescence intensity of 
CD25 expression ≥10-fold the negative cut-off were 
classified as CD25high as previously reported [11] (Fig-
ure  1d). Our data highlighted a significantly higher 
frequency of CD4+ CD25high FoxP3+ cells in AML 
samples (0.83 ± 0.75%) than in controls (0.19 ± 0.15%) 
(P  =  0.012) (Figure  1e), whereas no difference were 
observed in the frequency of CD4+ CD25+ FoxP3+ 
cells (P = 0.38, data not shown).
Altered frequency and cytokine profile were already 
been described in AML but not for all of these subsets of 
CD4+ cells in the same time and anyway, may suggest a 
global alteration of patient immune response.
Increased IL‑17/IL‑10‑secreting cells in the peripheral 
blood of AML patients
To deepen this aspect, we also evaluate the ability of 
the increased Th17 cells to simultaneously produce or 
secrete other cytokines, focusing on IFN-γ and IL-10 [21, 
23–25] (Figure 2a, b). Intriguingly, we observed a strong, 
statistically significant increase in the frequency of CD4+ 
IL-17/IL-10 double secreting cells in AML patients com-
pared to HV (0.54  ±  0.63 and 0.075  ±  0.145% respec-
tively; P = 0.002) (Figure 2c), whereas the percentage of 
IL-17  +/IFN-γ+ cells remained unchanged (P  =  0.39) 
(Figure  2d). No correlation was observed with spe-
cific karyotype, molecular biology mutations or Treg 
frequency.
The increase of IL-10+ Th17, together with the afore-
mentioned global CD4+ altered frequency, taking into 
account the singular infectious susceptibility of AML 
patients and the physiological protective role of Th17 
cells, seem to strengthen the hypothesis of a reduced 
immune response in these patients.
T cell immune response abnormalities after stimulation 
with C. Albicans
In order to evaluate the functional effects of the observed 
alterations, we analyzed intracellular IFN-γ expression of 
CD4+ cells from HV and AML patients stimulated with 
(See figure on next page.)
Figure 1 Alterations in T helper cells from HV and untreated AML patients. a Representative dot plots of cytokine production by CD4+ cells iso-
lated from a HV before and after in vitro priming with IL-6 and then with phorbol 12-myristate 13-acetate (PMA) and ionomycin (I). b Representative 
dot plots of CD4+ cells from an AML patient before and after stimulation with IL-6 and PMA + I. c Pooled data obtained after stimulation from 30 
HV (white circles) and 30 AML patients (black circles) and mean values (bars). d Gating strategy used to identify the CD4+ CD25highFoxP3+ cells.  
e Mean and standard deviation of Treg frequency from HV and AML patients.
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C. Albicans with or without depletion of IL-17-secreting 
cells (Figure 3a).
As shown in Figure 3b, the number of IFN-γ+ cells in 
not depleted control samples was 2.4-fold lower in AML 
compared to HV (0.5 ± 0.2 and 1.2 ± 0.6% respectively; 
P =  0.025). Interestingly, in patients the IFN-γ produc-
tion increased after IL-17-secreting cells depletion 
(2.3 ± 0.7%; P = 0.0005) (Figure 3b). Conversely, in HV, 
the depletion of IL-17-secreting cells did not induce sig-
nificant changes in the production of IFN-γ (P = 0.21).
This in vitro functional proof is in line with the hypoth-
esis of a reduced immune response in AML caused by 
altered Th17 cells; on the contrary, in HV the depletion of 
Th17 cells did not change the IFN-γ response, probably 
because under physiological conditions, they are not able 
to make that, alone.
The impairment of T cells after direct and indirect 
allogeneic co‑culture with CD33+ leukemic blasts
To investigate the role of leukemic cells in T cell changes, 
we performed direct and indirect co-cultures of CD4+ 
cells obtained from 15 HV and CD33+ blast cells mag-
netically isolated from 15 AML patients. A cytokine pat-
tern similar to that found in AML patients was observed 
in CD4+ co-cultured directly at a 1:1 ratio, with a signifi-
cant reduction in IFN-γ (P =  0.0008) and IL-4-positive 
cells (P = 3.2E−05) and a strong increase in the percent-
age of CD4+ IL-17A/IL-10-secreting cells (0.02  ±  0.05 
and 0.56 ± 0.5% before and after co-culture respectively; 
P  =  0.008). The above described cytokine alterations 
were also present when blasts and CD4+ cells were phys-
ically separated by a membrane (Figure 4a). In both co-
culture methods, these alterations were not observed at 
CD33+ and CD4+ ratios of 1:5 and 1:10 (Figure 4b).
These finds suggest that the changes observed in CD4+ 
cells cytokine profile were directly induced by leukemic 
cells probably by soluble factors.
Altered T cell cytokine production after depletion 
of CD33+ blasts in samples from AML patients
To provide other evidence of the blast action on CD4+ 
cells, we characterize the pattern of cytokine expression 
in AMLs before and after depletion of CD33+ blasts 
(Figure  5a). When patient CD4+ T cells were depleted 
of CD33+ cells, the former regained a capacity to pro-
duce IFN-γ and IL-4 similar to that of HV (P = 0.007 and 
P  =  0.0001, respectively) whereas Th17 cell frequency 
tended to decrease but not significantly probably due to 
the high standard deviation among samples (Figure 5b). 
Interestingly, IL-17/IL-10-releasing cells significantly 
decreased after CD33+ removal, suggesting the involve-
ment of blasts also in maintaining the immunosuppres-
sive state in AML patients.
Discussion
AML patients at the onset of disease and during chem-
otherapy are at high risk of severe and potentially fatal 
infections [2–4], but such conditions cannot be attrib-
uted to neutropenia alone. Indeed, concomitant reduced 
immune surveillance [9, 10, 12, 13], favors this infectious 
trend, worsens prognosis and limits therapeutic possi-
bilities [3]. Multiple mechanisms of immunosuppression 
have been identified including indoleamine 2, 3-dioxy-
genase [9] and CD200 glycoprotein overexpression [10], 
an enhanced Treg activity [11], an impaired dendritic cell 
maturation [12] and PD1- PDL1 axis alteration [13].
Figure 2 IL-10 and IFN-γ intracellular production by Th17 cells in 
HV and AML patients. a Representative flow cytometric data of IL-17 
and IL-10 double release by CD4+ T cells from HV and AML primed 
with IL-6 and PMA + I. b Representative dot plots of IL-17 and IFN-γ 
simultaneous production from a HV and an AML patient. c IL-17/
IL-10 pooled data from HV (white circles) and AML patients (black 
circles) and mean values (bars). The frequency of CD4+ T cells that 
simultaneously secreted IL-17 and IL-10 was 7.5-fold increased in 
AML patients compared with HV. d IL-17 and IFN-γ production data 
derived from the entire series are shown as mean and standard devia-
tion The concomitant intracellular production of IFN-γ and IL-17 by 
CD4+ cells was not significantly different from that of HV or patients 
(P > 0.05).
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More recently, another immunosuppressive mecha-
nism was described, attributing defective immunological 
synapse formation to T cells [6]. All these mechanisms 
cooperate to suppress immune control on leukemia cells 
and infections, and also reduce the effect of vaccina-
tion or other adoptive T cell transfer strategies [7]. Nev-
ertheless, the immune system may also be effective in 
controlling AML, as occurs in hematopoietic stem cell 
transplantation [8], and exploring additional ways to use 
such weapon could have a strong impact on the progno-
sis of these patients.
To our knowledge no convincing correlation has yet 
been found between immunosuppression, or specific 
T cell dysfunction, in AML and the infections to which 
AML patients are susceptible. Th17 cells, a particular 
subset of CD4+ cells and their respective cytokines, play 
a pivotal role in the inflammatory response and auto-
immune diseases [15–18] and also direct the defense 
against bacterial and fungal infections of the gastroin-
testinal tract, skin, airways and lungs [26–28]. However, 
their function in several tumor types is controversial [19, 
21, 22], and their involvement in hematological malig-
nancies, in particular AML, remains to be defined [29–
36]. Although our results confirmed previously published 
data [31, 33–36] showing statistically higher Th17 cell 
percentages in the peripheral blood of newly diagnosed 
AML patients compared to HV, the alteration in our 
study was observed together with a significant reduction 
Figure 3 IFN-γ production by CD4+ cells stimulated with C. Albicans before and after depletion of IL-17-secreting cells. a CD4+ cells were 
stimulated for 24 h with peptides from C. Albicans, then IL-17- secreting cells were then immunomagnetically depleted and negative fraction was 
cultured for a further 24 h in the presence of C. Albicans peptides and analyzed for intracellular IFN-γ expression. Representative dot plots of CD4+/
IFN-γ+ cells from HV and AML patient before and after depletion of IL-17-secreting cells are shown. b Pooled data from 5 HV and 5 AML patients 
are shown as mean values and standard deviation (n.s. not significant).
Figure 4 CD33+ blast involvement in inducing alterations in cytokine production by Th1,Th2 and Th17. a CD4+ cells isolated from 15 HV and 
CD33+ cells from 15 AML were co-seeded in a 1:1 ratio in the same well [direct co-culture (CC)] or in a transwell cell culture system (indirect CC). All 
samples were stimulated with IL-6 and PMA + I as previously described. At the end of stimulation, T cell immunophenotypic and cytokine secretion 
analysis were achieved. Data (mean and standard deviations) from direct or indirect CC were compared with pooled data obtained from 15 HV 
(*P < 0.05, **P < 0.005, ***P < 0.0005). b HV CD4+ cells and CD33+ blasts were directly or indirectly co-seeded in 1:5 and 1:10 ratios, respectively. All 
samples were stimulated with IL-6 and PMA + I and then analyzed for IFN-γ, IL-4 and IL-17 production and IL-17 and IL-10 simultaneous secretion. 
Data are expressed as mean and standard deviation (P > 0.05).
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in Th1 and Th2 frequencies. Moreover, a substantial 
increase in Tregs was observed, as previously reported by 
Szczepanski et al. [11].
Several studies hypothesized a role for Th17 cells 
in the pathogenesis of AML, but conflicting data on 
the different prognostic significance assigned to these 
cells [31–33] suggest an incomplete understanding of 
the mechanisms involved. In our opinion, the clinical 
presentation of AML patients, frequently affected by 
severe fungal or bacterial infections, is the most impor-
tant event to be taken into account together with the 
increased percentage of Th17 cells [31, 33, 36], as con-
firmed in our experiments. Indeed, these two events are 
clearly conflicting, given the physiological role of defense 
of Th17 cells. For this reason, we also performed a more 
in-depth investigation into the ability of Th17 cells to 
produce IL-17 simultaneously with other cytokines, 
focusing our research on IL-10 [23] and IFN-γ [21]. A 
simultaneous production of these cytokines has already 
been demonstrated in Th17 [21–23, 25, 44], in line with 
their plasticity [14], and may also be a sign of their epige-
netic transdifferentiation into other T cell types, such as 
Tregs [22, 23], which, themselves, may differentiate into 
FOXP3+ IL-17A cells [44] or Th17 Th1-like cells, secret-
ing IFN-γ [20, 21].
We observed a significantly higher increase in the 
frequency of CD4+ IL-17A+/IL-10+ secreting cells 
in AML patients than in HV, whereas the percent-
age of IL-17A+/IFN-γ+ cells remained unchanged. 
Our results thus suggest that the substantial imbalance 
between IL-17/IL-10-producing cells (the involvement 
of FoxP3+IL-17A+IL-10+ cells cannot be excluded) and 
IL-17A/IFN-γ-producing cells, together with a reduced 
frequency in Th1 and Th2 cells, may act as an additional 
immunosuppressive factor in these patients, altering the 
physiological role of Th17, contributing to the infections 
and probably promoting leukemia escape. Furthermore, 
as Th17 cells are long-lived cells with a stem-like molecu-
lar signature [37], their immunosuppressive capacity in 
leukemia may be powerful and more durable.
Figure 5 CD33+ cells are required for maintaining the altered cytokine pattern produced by T cells. a The scatter plot shows the blast compart-
ment before and after the CD33 depletion. The dot plots show how the intracellular cytokine production changes before and after blast depletion 
on the same patient. All samples were stimulated with IL-6 for 24 h and PMA + I for 5 h. b Pooled data are shown as mean and standard deviation 
(*P < 0.05, ***P < 0.0005).
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Moreover, we demonstrated that the immune response 
of CD4+ cells isolated from patients was strongly 
reduced against an infective antigen of fungal origin and, 
notably, that the selective depletion of Th17 cells from 
the culture, led to a restoration of IFN-γ production.
To investigate the role of circulating leukemic blasts in 
the observed alteration, we selected CD33+ cells after 
depletion of myeloid differentiated cells. All the changes 
observed in Th17 were induced in vitro by CD33+ leuke-
mic cells, as confirmed by direct and indirect co-cultures 
of healthy CD4+ cells and AML peripheral blasts. Given 
that in both co-culture the intensity of T alterations were 
similar, we hypothesized that leukemic cells action was 
mediated by soluble factors.
Moreover, patient T cells, depleted of CD33+ blasts, 
regained the capacity to produce levels of IFN- γ and IL-4 
similar to those of HV and showed a decreased ability to 
simultaneously produce IL-17 and IL-10. Therefore all of 
the above data suggested the involvement of blasts also 
in maintaining the immunosuppressive state in AML 
patients.
Conclusions
Aside from the known immunosuppressive mechanisms 
of AML [9–13], we identified a novel process induced 
by leukemic cells via soluble factors through which Th17 
are converted into IL-17/IL-10-secreting cells, creating 
an environment with reduced immune control and thus 
probably favoring leukemia immune escape. Moreo-
ver, for the first time we can hypothesize a direct con-
nection between the severe infective problems of AML 
patients and specific T cell alterations. The frequency of 
the immunosuppressive IL-17/IL-10-secreting cells in 
patients, needs more investigations but could represent 
a novel, simple, prognostic tool to identify the relative 
risk of severe infections and, perhaps, an increased risk of 
relapse for AML. Finally, although the role of Th17 cells 
in AML warrants further investigation, their long-last-
ing activity and plasticity could be used to convert these 
cells towards a tumor suppressor activity, making them a 
potential target for AML immunotherapy.
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